C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global C-reactive Protein Testing Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.21 Billion by 2031, reflecting a CAGR of 2.11%. This diagnostic method, which quantifies C-reactive protein in blood samples, serves as a vital biomarker for systemic inflammation, bacterial infections, and cardiovascular risks. Growth is largely fueled by the rising incidence of chronic cardiovascular and inflammatory conditions that require ongoing patient monitoring and risk assessment. For instance, the American Heart Association reported that the global prevalence of cardiovascular disease reached approximately 612 million cases in 2025, highlighting the critical need for inflammatory markers. Additionally, the market is bolstered by an aging global population and a noticeable transition toward decentralized point-of-care testing solutions.

However, a major obstacle hindering market progress is the strict regulatory landscape combined with variable reimbursement policies across different regions. These administrative and economic hurdles often postpone the commercial authorization of novel testing platforms and restrict the financial viability of high-sensitivity diagnostic tools for healthcare providers. Consequently, these barriers limit the broader adoption and market penetration of advanced diagnostic solutions.

Market Drivers

The escalating burden of chronic and inflammatory diseases acts as a primary engine for the Global C-reactive Protein Testing Market's development. Because systemic inflammation is a core component of cardiovascular diseases, diabetes, and autoimmune conditions, the clinical imperative for precise biomarkers to track disease progression has grown stronger. Medical professionals are increasingly utilizing C-reactive protein assays for early inflammation detection and effective therapy management, especially considering the vast impact of noncommunicable diseases. According to the World Health Organization's April 2024 fact sheet, noncommunicable diseases are responsible for 41 million deaths annually, accounting for 74% of global mortality, a statistic that underscores the necessity for rigorous diagnostic protocols and high demand for testing in both hospital and outpatient environments.

Simultaneously, the market is being shaped by the growing integration of point-of-care testing platforms, which decentralize diagnostic processes and facilitate swift clinical decision-making. These portable devices enable immediate protein level analysis outside of traditional laboratories, aiding in the differentiation between bacterial and viral infections and helping to minimize inappropriate antibiotic use. Major manufacturers are expanding their capabilities to address this shift towards decentralized care; for example, Abbott reported worldwide Diagnostics sales of USD 2.4 billion in their October 2024 results, highlighting the persistent demand for accessible diagnostic tools. Furthermore, demographic trends identified by the United Nations in 2024 indicate a significant rise in the global population aged 65 and older, increasing the patient base susceptible to inflammatory conditions and driving the need for regular health monitoring.

Market Challenges

Growth in the Global C-reactive Protein Testing Market is heavily constrained by a rigorous regulatory environment and inconsistent reimbursement strategies. Manufacturers must navigate complex and shifting compliance standards that prolong approval processes and escalate development expenses. This regulatory pressure forces companies to divert crucial capital away from the research and development of high-sensitivity assays, thereby delaying the commercial launch of advanced diagnostic innovations. As a result, the uncertainty surrounding approval pathways often deters companies from introducing new products in major markets, ultimately limiting the diagnostic options available to healthcare providers for effective patient monitoring.

In addition to regulatory hurdles, ambiguous reimbursement frameworks introduce financial risks that inhibit the uptake of these tests. Clinical laboratories are frequently hesitant to invest in modern diagnostic platforms lacking clear payment assurances, a factor that directly impedes market penetration. Data from MedTech Europe in 2025 highlighted the severity of this issue, revealing that certification costs under the In Vitro Diagnostic Regulation surged by up to 100% compared to earlier standards, prompting a 40% reduction in large manufacturers choosing the European Union as their primary launch region. This demonstrates how administrative and economic impediments actively suppress the market's potential for broader expansion.

Market Trends

The utilization of CRP testing within Antimicrobial Stewardship Programs is fundamentally transforming market demand as healthcare systems incorporate diagnostic algorithms into national strategies against drug resistance. Institutional protocols increasingly require CRP screening before antibiotic administration to ensure alignment with global stewardship objectives, thereby elevating the assay from a standard diagnostic tool to a vital element of regulatory compliance. This shift drives the acquisition of rapid testing platforms as critical infrastructure for public health adherence, particularly for validating treatment choices in respiratory infections. As noted in an Abbott article from January 2024, utilizing C-reactive protein point-of-care testing alongside communication training has been demonstrated to decrease antibiotic prescribing by over 60%.

Concurrently, the widespread application of High-Sensitivity CRP (hs-CRP) for cardiovascular risk stratification is broadening the test's scope from monitoring acute inflammation to long-term preventative cardiology. Clinicians are placing greater emphasis on hs-CRP to detect residual inflammatory risks in asymptomatic individuals, enabling early intervention strategies that complement traditional lipid management. This trend is gaining momentum as fresh clinical evidence confirms the biomarker's ability to predict future adverse events over long periods, encouraging providers to add these assays to routine screenings. For instance, research presented at the European Society of Cardiology Congress in August 2024 indicated that women with elevated C-reactive protein levels faced a 70% higher risk of heart disease compared to those with the lowest levels.

Key Players Profiled in the C-reactive Protein Testing Market

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

Report Scope

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories:

C-reactive Protein Testing Market, by Assay Type:

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

C-reactive Protein Testing Market, by Detection Range:

• hs-CRP
• Conventional CRP
• cCRP

C-reactive Protein Testing Market, by Disease Area:

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

C-reactive Protein Testing Market, by End-Use Industry:

• Hospitals & Clinics
• Laboratories
• Assisted Living Healthcare Facilities
• Homecare
• Others

C-reactive Protein Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.